An organization representing American pharmacists is raising the alarm over surging side effects caused by Covid mRNA “vaccines.”
The warning was issued in a recent “COVID-19 Vaccine Safety Update” report published by U.S. Pharmacist.
The report notes that the adverse effect (AE) profile of the two mRNA COVID-19 “vaccines” (Pfizer and Moderna) and the recombinant protein Covid shot (Novavax) markedly differ.
mRNA vaccines are associated with myocarditis and pericarditis.
Both myocarditis and pericarditis are forms of inflammation in and around the heart.
The inflammation restricts the heart’s ability to pump blood around the body.
Myocarditis and pericarditis can lead to cardiac arrest, blood clots, strokes, and sudden death.
However, they can often be symptomless, meaning many sufferers go undiagnosed until it’s too late.
As a result, doctors often refer to these conditions as a “silent killer” or a “ticking time bomb.”
“A definitive diagnosis of myocarditis requires that an endomyocardial biopsy be performed, which was not typically done during the pandemic,” the report notes.
“A diagnosis is based on clinical presentation and laboratory data.”
The report also raises concerns about the lack of accurate safety reporting for the “vaccines.”
“Patients may have received different brands for their original vaccine and subsequent boosters, which makes data collection and establishing correlation complicated,” the report notes.
The U.S. Centers for Disease Control and Prevention’s (CDC) website provides information on Covid “vaccine” safety, healthcare providers, and parent/caregiver information on vaccine safety.
The website also contains links to the U.S. Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink, V-safe, the Clinical Immunization Safety Assessment project, and the COVID-19 Vaccine Pregnancy Registry.
VAERS serves as the nation’s early warning system to monitor for potential vaccine safety problems.
Pharmacists have a professional obligation to file a report if an adverse event (AE) to a “vaccine” is suspected.
The report found that adverse reactions are most commonly associated with the mRNA Covid “vaccines” from Pfizer and Moderna.
Overall, Covid mRNA vaccine-associated myocarditis accounted for 68% of all cases of vaccine-associated myocarditis or pericarditis reported to VAERS between January 1, 2021, and July 20, 2021.
AEs to the Moderna injections from January 1, 2021, through October 27, 2022, accounted for 1,942 AEs or 0.28% of all adverse reactions reported to VAERS.
These adverse reactions included myocarditis (25.18%, 489 reports); acute myocardial infarction (24.46%, 475 reports); bradycardia (14.93%, 290 reports); and pericarditis (14.47%, 281 reports).
For PmRNACV, the observed risk of myocarditis is highest in males aged 12 to 17 years, whereas for MmRNVACV, the observed risk is highest in males aged 18 to 24 years.
Analysis of data for adolescents aged 12 to 17 years from VigiBase, the World Health Organization’s (WHO) global Individual Case Safety Report database, found a statistically significantly elevated adjusted reporting odds ratio (OR) of 19.61 (95% CI 14.05-27.39) for myocarditis/pericarditis for both Covid mRNA “vaccines.”
These mRNA injections accounted for over 95% of all Covid vaccinations.
The incidence of pericarditis or myocarditis after the Pfizer shot in adolescent patients (median age 15 years) presenting to the emergency department with cardiovascular symptoms was found to be approximately 7%.
Hospitalization rates for myocarditis/pericarditis vary, with reports of up to 87%.
Risk factors for pediatric intensive unit admission for myocarditis are abnormal electrocardiographic findings and abnormal serum troponin levels in the pediatric emergency department.
An increased rate of reports among individuals aged 16 to 17 years was seen when the second dose of PmRNACV was administered with a short (i.e., <30 days) inter-dose interval (21.3 per 100,000; 95%CI, 11.0-37.2).
Other reports have found that males aged 15 to 24 years are at the highest risk of developing myocarditis following the second Covid mRNA “vaccine.”
Children aged 5 to 11 years also saw increased cases of myocarditis and pericarditis.
However, the younger age group appears to be at a lower risk of developing myocarditis and pericarditis than adolescents aged 12 to 15 years.
The highest rates of myocarditis and pericarditis were reported for the Moderna injection, with an overall incidence of about 10/100,000 and around 50/100,000 in men aged <40 years.
There was consensus among the reports that those at greatest risk of developing myocarditis were men aged between 12 and 39 years; an elevated rate of vaccine-associated myocarditis is not seen in those aged >50 years.
However, pericarditis is most often seen in men in this group.
The report concludes by calling for more transparency regarding the health risks associated with Covid “vaccines.”
It notes that pharmacists play a major role in educating the public about the “safety” of “vaccines” but this task is being hindered by “much misinformation about the safety profile” of the injections.
READ MORE – Bombshell Study Confirms Covid ‘Vaccines’ Alter Human Behavior
